Postdischarge Anticoagulation Use Reduces VTE Risk After COVID-19 Hospitalization
Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.
Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.
Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.
In this interview, Chun discussed recommendations for internal medicine physicians to give older adults for slowing aging as well as evidence for statins.
A retrospective challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.
This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.
New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.
Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.
Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.
Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.